ArticleCureus2025
DNAJB9 Fibrillary Glomerulonephritis Following Rituximab-Based Therapy: A Case of Temporary Renal Recovery.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 63-year-old man, with no relevant history, developed acute kidney injury with an elevated serum creatinine level of 314 µmol/L associated with hypertension, a nephrotic syndrome, without hematuria. Kidney biopsy revealed a glomerular-specific deposition of DnaJ homolog subfamily B member 9 (DNAJB9). Fibrillary glomerulonephritis was diagnosed. The patient received corticosteroids, rituximab (1 g at day 1 and day 15; 1 g at month 6), and nephroprotection. Kidney dysfunction initially worsened (creatinine 513 µmol/L), and peritoneal dialysis was initiated. Partial renal function recovery was observed after the rituximab-maintenance dose, allowing dialysis discontinuation for one year (October 2023 to September 2024). In some studies, rituximab-based therapy was associated with stabilization of disease progression. As observed in our case, it could be considered on a case-by-case basis, with a possible benefit for partial treatment response and time-limited disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.